BiondVax using MedInstill's innovative technology, will provide a unique and versatile solution for seasonal and pandemic flu vaccine

Ness Ziona, Israel - December 17, 2015 - BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) and MedInstill Inc., a leading provider of technologies for the contamination-free manufacturing and delivery of pharmaceuticals, signed an agreement for vial filling using the INTACT technology. Under the agreement, MedInstill will provide the equipment and technology for manufacturing BiondVax's universal flu vaccine (M-001 vaccine), which will be incorporated into its advanced clinical program.

Using the INTACT technology, BiondVax will be able to offer its universal flu vaccine either as single dose vials for seasonal flu or as ready-to-use multiple-dose pouches for Government pandemic stockpiling of the M-001 universal flu vaccine.

The INTACT technology is characterized by high throughput and cost effectiveness needed for large-scale vaccinations and provides unparalleled surge capacity in times of flu outbreaks.

'We are excited with our collaboration with MedInstill, a strong partner in moving towards mass production of the M-001 universal flu vaccine. This technology enables an innovative vaccine coupled to a tailored solution for its various end uses,' said Dr. Ron Babecoff, CEO of BiondVax.

BiondVax Pharmaceuticals Ltd. issued this content on 2016-01-01 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 2016-01-01 17:50:19 UTC

Original Document: http://www.biondvax.com/2016/01/01/biondvax-and-medinstill-announce-collaboration-on-flu-vaccine-filling-using-intact-technology/